Market Indices
Latest News
 |
| ||
| ||
| ||
|
Price Targets
Swayampakula Ramakanth from H.C. Wainwright issued a price target of $7.00 for IPHA on 2026-08-10 16:27:19.The adjusted price target was set to $7.00.At the time of the announcement,
August 10, 2026 IPHA 22.83%
Market Movers
| Top Gainers (%) | |||||||||||||||||||
| STKH Steakholder Foods Ltd. | 4.18
122.34% | ||||||||||||||||||
| SLN Silence Therapeutics plc | 15.13
26.57% | ||||||||||||||||||
| BNR Burning Rock Biotech Limi | 11.07
25.51% | ||||||||||||||||||
| IPHA Innate Pharma S.A. | 2.13
22.83% | ||||||||||||||||||
| LU Lufax Holding Ltd | 1.72
14.33% | ||||||||||||||||||
| AKTX Akari Therapeutics, Plc | 7.83
11.86% | ||||||||||||||||||
| PPBT Purple Biotech Ltd. | 1.59
11.19% | ||||||||||||||||||
| CD Chaince Digital Holdings | 2.95
11.13% | ||||||||||||||||||
Annual/Quarterly Reports Summary
Summit Therapeutics Inc. (SMMT) Quarterly Report: What Does It Reveal About Their Sector Performance
May 1, 2025 SMMT 5.59%
In a landscape of rising revenues and increasing operational costs, the company navigates challenges with a focus on innovation and sustainability. Despite a dip in net income and profit declines...
February 5, 2025 TEVA 1.89%
In a year marked by resilience, the company celebrated record revenues of $25 billion, driven by strong ticket sales and operational efficiency. With a focus on North America, it reduced...
January 27, 2025 TEVA 1.89%